factors for pts with acute myocardial infarction (AMI). However, the relationship between them and their individual role during the in-hospital phase and in the long-term after hospital discharge are not clearly understood.
Methods:
We analyzed retrospectively 1429 pts with AMI (mean age 64.5 + 0.34 y.o., 72.5% men) treated in a single tertiary institution, included prospectively in a dedicated databank and followed for up to 11.7 years (mean survival time=8.7 years). Correlations with mortality were carried out utilizing the Chi-square/log-rank tests and logistical/Cox stepwise regression models as indicated.
Results: (1) In-hospital phase: Death rates for diabetics and nondiabetics were, respectively, 12.7% and 9.6% (P=0.08); by univariate logistic regression, glucose level (as continuous variable) at hospital arrival was highly correlated with mortality (P<0.001); putting together both variables in a multivariate model, the figures were P=0.74 for DM and P<0.001 for glucose level (GL); in the adjusted model with 15 baseline variables included, GL remained correlating significantly with mortality (P<0.001), along with age (P<0.001), ST-elevation AMI (P=0.03), and history of heart failure (P<0.001) and hypertension (P=0.005). (2) Long-term outcome: The mean survival time for nondiabetics and diabetics were, respectively, 9.02 and 7.88 years (P<0.001); GL showed a borderline correlation with mortality (P=0.046); with both variables in the same model, the figures were P= 0.001 for DM and P=0.75 for GL; in the multivariate model with all 15 variables included, history of DM remained correlating significantly with mortality (P=0.022), along with age (P<0.001) and history of previous AMI (P<0.001), heart failure (P=0.01) and stroke (P=0.013). In a multivariate model excluding in-hospital deaths, DM remained correlating significantly with mortality (P=0.041).
Conclusions:
During the in-hospital phase the glucose level at hospital arrival is a better mortality predictor than DM; on the other hand, DM is a good mortality predictor in the long-term follow up after AMI, contrary to glucose level.
